scholarly journals Community studies on hepatitis B in Rajahmundry town of Andhra Pradesh, India, 1997–8: unnecessary therapeutic injections are a major risk factor

2000 ◽  
Vol 125 (2) ◽  
pp. 367-375 ◽  
Author(s):  
J. SINGH ◽  
R. BHATIA ◽  
S. K. PATNAIK ◽  
S. KHARE ◽  
D. BORA ◽  
...  

In Rajahmundry town in India, 234 community cases of jaundice were interviewed for risk factors of viral hepatitis B and tested for markers of hepatitis A–E. About 41% and 1·7% of them were positive for anti-HBc and anti-HCV respectively. Of 83 cases who were tested within 3 months of onset of jaundice, 5 (6%), 11 (13·3%), 1 (1·2%), 5 (6%) and 16 (19·3%) were found to have acute viral hepatitis A–E, respectively. The aetiology of the remaining 60% (50/83) of cases of jaundice could not be established. Thirty-one percent (26/83) were already positive for anti-HBc before they developed jaundice. History of therapeutic injections before the onset of jaundice was significantly higher in cases of hepatitis B (P = 0·01) or B–D (P = 0·04) than in cases of hepatitis A and E together. Other potential risk factors of hepatitis B transmission were equally prevalent in two groups. Subsequent studies showed that the majority of injections given were unnecessary (74%, 95% CI 66–82%) and were administered by both qualified and unqualified doctors.

Author(s):  
Karlla A A Caetano ◽  
Fabiana P R Bergamaschi ◽  
Megmar A S Carneiro ◽  
Raquel S Pinheiro ◽  
Lyriane A Araújo ◽  
...  

Abstract Background People living in settlement projects represent an emergent rural population in Brazil. Data on their health is scarce and there are no data on viral hepatitis in this population. This study investigated the epidemiology of viral hepatitis A-E in residents of settlement projects in central Brazil. Methods During 2011 and 2012, 923 people living in rural settlements in central Brazil were interviewed and tested to estimate the prevalence of exposure to viral hepatitis A-E, to identify the circulating hepatitis B virus (HBV)/hepatitis C virus (HCV) genotypes and risk factors for HBV exposure and to evaluate adherence to the hepatitis B vaccination series. Results Overall, 85.9, 3.9, 0.4 and 17.3% of individuals showed evidence of exposure to hepatitis A virus (HAV), hepatitis E virus, HCV and HBV, respectively. Among HBV-DNA positive samples (n=8), subgenotypes A1 (n=3) and A2 (n=1) and genotype D/subgenotype D3 (n=4) were identified. Hepatitis D virus superinfection was detected in 0/16 HBsAg-positive participants. A total of 229 individuals showed serological evidence of HBV vaccination. In total, 442 settlers were eligible for vaccination, but only 150 individuals completed the vaccine series. All anti-HCV-positive samples (n=4) were also HCV-RNA positive and identified as subtype 1a. Conclusions The intermediate endemicity of HAV, the higher prevalence of HBV exposure compared with urban areas and the low compliance with HBV vaccination requires preventive measures focused on rural populations, emphasizing the need for HAV and HBV vaccination.


2011 ◽  
Vol 44 (5) ◽  
pp. 546-550 ◽  
Author(s):  
Claudia Suellen Ferro de Oliveira ◽  
Adenielson Vilar e Silva ◽  
Kemper Nunes dos Santos ◽  
Amanda Alves Fecury ◽  
Marcella Kelly Costa de Almeida ◽  
...  

INTRODUCTION: Viral hepatitis is a major public health concern in Brazil. There are few past studies on this issue, especially among riparian communities. This study aims at determining the seroprevalence of viral hepatitis B and C in the riparian community of Pacuí Island, within the Cametá municipality of Pará State, Brazil. Moreover, this study aims to investigate the principal risk factors that this community is exposed to. METHODS: The current study has accessed blood samples from 181 volunteers who have answered an epidemiological questionnaire. Analyses on serological markers have been tested with commercial ELISA kits for detecting HBsAg, total anti-HBc, anti-HBs, and anti-HCV. Within seroreactive patients for HCV, RT-PCR and line probe assay have been performed to identify the viral genotype. RESULTS: In the serological marker analysis for hepatitis B, no reactivity for HBsAg, rate of 1.1% for total anti-HBc, and rate of 19.3% for anti-HBs have been observed. On hepatitis C, 8.8% seroprevalence has been found, in which 62.5% have gotten viral RNA. Among the risk factors studied, the following have been highlighted: non-use of condoms, sharing of cutting instruments, use of illicit drugs, and reports of family disease with HBV or HCV. CONCLUSIONS: The vaccination coverage against HBV is low, and the high prevalence of HCV within this community has been observed.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mohammad Amin Behzadi ◽  
Victor Hugo Leyva-Grado ◽  
Mandana Namayandeh ◽  
Atoosa Ziyaeyan ◽  
Roya Feyznezhad ◽  
...  

Abstract Background Viral hepatitis is a global public health problem affecting millions of people worldwide, causing thousands of deaths due to acute and persistent infection, cirrhosis, and liver cancer. Providing updated serologic data can improve both surveillance and disease control programs. This study is aimed to determine the seroprevalence of markers for viral hepatitis (A, B, C, D and E) and the epidemiology of such infections in the general population of southern Iran’s Hormozgan province. Methods Between 2016 and 2017, a total of 562 individuals with ages ranging from 1 to 86 years, who visited governmental public laboratories for routine check-ups, were tested for the presence of serological markers to hepatitis virus types A to E using enzyme-linked immunosorbent assays. Results The overall anti-hepatitis A virus (HAV) antibody seroprevalence was 93.2% (524/562). The prevalence of anti-hepatitis E virus (HEV) antibodies was 15.8% (89/562) among which 1.6% (9/562) of the seropositive individuals also had evidence of recent exposure to the virus (IgM positivity). Two and a half percent (14/562) were positive for hepatitis B surface (HBs) antigen, whereas 11.6% (65/562) tested positive for anti-hepatitis B core (HBc) antibodies. Among anti-HBc positive patients, 11% (7/65) had HBs Ag and 5% (3/65) were positive for anti-hepatitis D virus (HDV) antibodies. The prevalence of anti-hepatitis C virus (HCV) antibodies was 0.7% (4/562). The seroprevalence of anti-HAV, HEV IgG, anti-HBc antibodies, and HBs Ag increased with age. Conclusion The present study confirms a high seroprevalence of HAV infection among the examined population and reveals high levels of endemicity for HEV in the region. Planned vaccination policies against HAV should be considered in all parts of Iran. In addition, improvements on public sanitation and hygiene management of drinking water sources for the studied area are recommended.


BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e042065
Author(s):  
Chin Man Poon ◽  
Denise P Chan ◽  
Shui Shan Lee ◽  
Ngai Sze Wong

IntroductionDifferences in immunisation policies have significantly reshaped the epidemiology of hepatitis A and B in the population. Assessment of the susceptibility and transmission potential of these two types of vaccine-preventable hepatitis would enhance the capacity of public health authorities for viral hepatitis elimination. Focusing on Hong Kong, the objectives of this study comprise the determination of the population-level seroprevalence of hepatitis A and B and an examination of the risk factors for virus transmission and the population impacts of vaccinations.Methods and analysisThis is a cross-sectional household survey on hepatitis A and B. By using socially homogeneous building groups as sampling frame, eligible members of 1327 spatially selected households would be invited to complete a questionnaire and provide blood samples for serological testing (anti-hepatitis A virus, hepatitis B surface antigen, hepatitis B surface and core antibody). The main measures comprise a set of metrics on the prevalence of hepatitis A and B. Analysis would be conducted to examine the association of risk factors with the tested markers and describe the attitudes towards viral hepatitis vaccination.Ethics and disseminationEthical approval from the Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee, and approval for laboratory safety from the Chinese University of Hong Kong have been obtained. The study results will be presented in scientific forums to update on the epidemiology of hepatitis A and B and inform the development of new vaccination strategies in Hong Kong.Trial registration numberNCT04371276.


Sign in / Sign up

Export Citation Format

Share Document